Neoadjuvant Therapy With Docetaxel and Ketoconazole in Patients With High-Risk Prostate Cancer: A Pilot Study
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Eligible patients with high-risk prostate cancer who are scheduled to undergo radical
prostatectomy will receive four cycles of therapy with ketoconazole and docetaxel prior to
surgery resection. A cycle of therapy is defined as 21 days (three weeks). Pharmacokinetic
analysis will be performed with the first and second cycle of therapy. All patients will be
evaluated for toxicity, tumor response, and recurrence.